Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Biomarker Development.

Because biomarker discovery helps stratify patients, signal resistance, and predict relapse

Understanding why some patients respond to therapies while others do not is critical to accelerating clinical trials and developing better treatments. Single-cell DNA and multi-omics analyses can untangle therapy resistance mechanisms that are impossible to obtain through traditional methodologies. The simultaneous detection of mutation profile and immunophenotype will help you discover new druggable targets, explore mechanisms of action, monitor patients, identify drug resistance as it develops, and stratify patients for clinical trials with greater efficiency.


Why Single Cell for Pharma Clinical Trials?

While great strides have been made in targeted therapies, improved biomarker discovery is needed to realize the full potential of precision medicine. Single-cell analysis of genotype and phenotype from the same cell can provide sensitivity and resolution for biomarker discovery unattainable by current bulk methods. Single-cell resolution can reveal treatment resistance mechanisms to better stratify patients in clinical trials. While on treatment, residual levels of disease can be detected with the high sensitivity of single-cell analysis. Characterizing clonal heterogeneity and tracking clonal evolution during treatment can then guide adaptive and rational combination therapies for better patient stratification and better clinical trial outcomes.

It is time to get to the ground truth of cancer

Identifying a person in a crowd
Improve patient stratification distinguishing responders from non-responders
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Dr. Andrew Wei, Monash University, Dr. Marina Konopleva, MD Anderson Cancer Center
Graph on patient chart
Monitor patients for minimal residual disease (MRD) with high sensitivity of single-cell analysis
Single-cell mutational profiling enhances the clinical evaluation of AML MRD

Dr. Ravindra Majeti, Stanford
Providing therapy to the right patients
Identify better therapies and guide adaptive/rational combination therapies
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

Agios Pharmaceuticals

“So far, we’ve had very good results using the Tapestri Platform in early phase trials to evaluate response and resistance to AML. The sensitivity provided by the assay may therefore be important for use as a surrogate endpoint for these studies.”

Marcia Eisenberg, CSO of LabCorp, GenomeWeb

Partnered with Leading Institutions




Argo Pharmaceuticals

Bristol Myers Squibb



Foundation Medicine



Science Exchange

Stelexis Therapeutics


The Tapestri Platform

The first and only single-cell multi-omics platform developed to reveal biomarkers that help stratify patients, signal resistance, and predict relapse.
Tapestri product image with an instrument, reagent kit and analysis software displaying a fish plot
Tapestri Platform
An end-to-end workflow from sample preparation to visualization with publication-ready insights for single-cell analysis.
Targeted panels provide focus on key regions of interest for efficient use of sequencing budget and analysis time.

Partnering with Mission Bio

To support you and your drug development, we provide full service as a strategic partner for you from single-cell assay design, sample processing, through to data analysis and visualization. Whether we offer services internally or in partnership with qualified CROs, we are dedicated to the accelerated success of your drug development programs.

Three icons including a light bulb and a data chart, a correlation graph, and a physician

Get Started

Contact us to discuss your project:

Featured Resources